金晶，研究員，博士研究生導(dǎo)師，國家高層次青年人才項(xiàng)目獲得者。主持國家重點(diǎn)研發(fā)計(jì)劃，國家自然科學(xué)基金面上項(xiàng)目等多項(xiàng)國家級(jí)課題。中國藥理學(xué)會(huì)呼吸藥理專業(yè)委員會(huì)副主任委員，中國藥理學(xué)會(huì)生化與分子藥理學(xué)專業(yè)委員會(huì)委員，中國藥理學(xué)會(huì)抗炎免疫委員會(huì)委員，中國民族醫(yī)藥學(xué)會(huì)藥理與毒理學(xué)分會(huì)常務(wù)理事，中國病理生理學(xué)會(huì)缺氧與呼吸專業(yè)委員會(huì)委員，北京環(huán)境誘變劑學(xué)會(huì)青年委員會(huì)副主任委員，《藥學(xué)學(xué)報(bào)》和《Acta Pharmaceutica Sinica B》青年編委。

長期從事腫瘤及炎癥等慢性疾病的發(fā)病機(jī)制研究和創(chuàng)新藥物研發(fā)。作為藥理學(xué)科負(fù)責(zé)人，參與完成2個(gè)1類新藥獲CFDA 臨床批件；參與完成3項(xiàng)成果轉(zhuǎn)化。在Nature Cell Biology, Advanced Sciences等發(fā)表論文15篇；獲得國內(nèi)外授權(quán)專利22項(xiàng)；主持國家重點(diǎn)研發(fā)計(jì)劃（2項(xiàng)）、國家自然科學(xué)基金等多項(xiàng)課題，參與國家“十二五”、“十三五”重大新藥創(chuàng)制、國家自然科學(xué)基金重大項(xiàng)目等多項(xiàng)課題。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1. Zhaoxin Zhang^#, Shuying Li^#, Fangfei Li^#, Qinyan Shi, Chengyong Tan, Xiaoying Wang, Mi Li, Yunbao Liu*, Jing Jin*, Yong Li*, Shishan Yu*. Meisoindigo Acts as a Molecular Glue to Target PKMYT1 for Degradation in Chronic Myeloid Leukemia Therapy, Adv Sci, 12(21): e2413676. （IF=14.1）

2. Chunyu Zhang^#, Fangfang Lai^#, Hang Gong^#, Shuying Li, Nan Xiang, Liuyi Que, Nina Xue, Mengyao Hao, Enjia Zhou, Xiaojian Wang*, Taigang Liang*, Jing Jin*. A Novel Dual Bruton’s Tyrosine Kinase/Janus Kinase 3 Inhibitor Wj1113 and its Therapeutic Effects on Rheumatoid Arthritis. MedComm, 6(7): e70207. (IF=10.7)

3. Zhenyuan Li^#, Shuying Li^#, Zeyu Xing^#, Quanchang Gu, Rongrong Du, Jianshuang Jiang, Xiang Yuan, Xu Zhang, Xiaoguang Chen, Nina Xue*, Peicheng Zhang*, Jing Jin*, Yanan Yang*. Discovery of Natural Ah Receptor Antagonists from Salvia miltiorrhiza Bunge and Synthesis of Analogs for Tumor Immunotherapy, J Med Chem, 67(2): 1243–1261. (IF=6.8)

4. Mengyao Hao^#, Rong Fu^#, Jun Tai^#, Zhenhuan Tian^#, Xia Yuan, Yang Chen, Mingjin Wang, Huimin Jiang, Ming Ji, Fangfang Lai, Nina Xue, Liping Bai, Yizhun Zhu, Xiaoxi Lv*, Xiaoguang Chen*, Jing Jin*. S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung, Acta Pharm Sin B, 13(3): 1110-1127（IF=14.7）

5. Mingjin Wang, Weida Wang, Shen You, Zhenyan Hou, Ming Ji, Nina Xue, Tingting Du, Xiaoguang Chen*, Jing Jin*. ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation of myeloid-derived suppressor cells. Acta Pharm Sin B, 13(12): 4733-4747. （IF=14.7）

6. Ruxuan Wang^#, Xiaoyi Yang^#, Shen You, Mengyao Hao, Jianguang Li*, Xiaoguang Chen*, Jing Jin*. Chlorogenic Acid Relieves the Lupus Erythematosus-like Skin Lesions and Arthritis in MRL/lpr Mice, Pharmaceuticals, 15(11): 1327. （IF=5.2）

7. Yaru Kong^#, Mengyao Hao^#, Aiping Chen^#, Tianxing Yi, Ke Yang, Peng Li, Yi Wang, Pengfei Li, Xinbei Jia, Han Qin, Yuwei Qi, Jie Ji*, Jing Jin*, Qian Hua*, Jun Tai*. SymMap database and TMNP algorithm reveal Huanggui Tongqiao granules for Allergic rhinitis through IFN-mediated, Pharmacol Res, 185: 106483 （IF=9.2）

8. Minjian Yang ^#, Huimin Jiang ^#, Zhuo Yang, Xue Liu, Hanyu Sun, Mengyao Hao, Jinping Hu*, Xiaoguang Chen*, Jing Jin*, Xiaojian Wang*. Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitor, Eur J Med Chem, 241: 114611. （IF=6.7）

9. Jingbo Zhang ^#, Huimin Jiang ^#, Songwen Lin ^#, Deyu Wu, Hua Tian, Lin Jiang, Yiman Cui, Jing Jin*, Xiaoguang Chen*, Heng Xu*. Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies, J Med Chem, 65(11): 8011-8028.（IF=7.3）

10. Xueju Wei^#, Yue Huo^#, Jingnan Pi^#, Yufeng Gao^#, Shuan Rao ^#, Manman He^#, Qinglv Wei, Peng Song, Yiying Chen, Dongxu Lu, Wei Song, Junbo Liang, Lingjie Xu, Haixia Wang, Guolin Hong, Yuehong Guo, Yanmin Si, Jiayue Xu, Xiaoshuang Wang, Yanni Ma, Shuyang Yu, Dongling Zou*, Jing Jin*, Fang Wang*, Jia Yu*. METTL3 preferentially enhances non-m6A translation of epigenetic factors and promotes tumourigenesi, Nat Cell Biol, 24(8): 1278–1290. （IF=21.3）